© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Alkermes plc (ALKS) stock declined over -1.66%, trading at $46.10 on NASDAQ, down from the previous close of $46.88. The stock opened at $46.14, fluctuating between $45.80 and $46.93 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 04, 2026 | 46.14 | 46.93 | 45.80 | 46.10 | 1.05M |
| Sep 03, 2026 | 48.01 | 48.29 | 46.71 | 46.88 | 898.12K |
| Sep 02, 2026 | 47.70 | 48.74 | 46.68 | 47.72 | 1.42M |
| Sep 01, 2026 | 47.00 | 47.34 | 46.65 | 47.20 | 1.19M |
| Aug 31, 2026 | 47.25 | 47.56 | 46.46 | 46.99 | 1.43M |
| Aug 28, 2026 | 48.82 | 48.82 | 47.25 | 47.41 | 1.43M |
| Aug 27, 2026 | 48.72 | 49.33 | 48.10 | 48.90 | 2.05M |
| Aug 26, 2026 | 49.23 | 49.35 | 48.46 | 49.16 | 660.78K |
| Aug 25, 2026 | 48.94 | 49.58 | 48.87 | 49.21 | 1.04M |
| Aug 24, 2026 | 48.05 | 49.03 | 47.64 | 48.87 | 1.3M |
| Aug 21, 2026 | 48.05 | 48.67 | 47.33 | 48.33 | 939.63K |
| Aug 20, 2026 | 49.37 | 49.86 | 47.93 | 48.02 | 1.56M |
| Aug 19, 2026 | 51.26 | 51.29 | 50.08 | 50.18 | 1.54M |
| Aug 18, 2026 | 50.10 | 50.42 | 49.46 | 49.48 | 970.91K |
| Aug 17, 2026 | 48.90 | 50.08 | 48.62 | 49.85 | 763.84K |
| Aug 14, 2026 | 49.37 | 50.02 | 48.65 | 49.06 | 1.27M |
| Aug 13, 2026 | 51.66 | 51.66 | 49.21 | 49.45 | 1.55M |
| Aug 12, 2026 | 49.22 | 50.53 | 48.50 | 50.28 | 1.32M |
| Aug 11, 2026 | 49.92 | 50.14 | 48.97 | 49.21 | 1.37M |
| Aug 10, 2026 | 48.39 | 49.81 | 48.39 | 49.40 | 1.51M |
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
| Employees | 2050 |
| Beta | 0.27 |
| Sales or Revenue | $1.66B |
| 5Y Sales Change% | 0.418% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |